Clinical Trial Update: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Raphamin for acute respiratory viral infection in children aged 12-18 has completed and results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Viral Infection

Drugs mentioned

• Raphamin (Raphamin)

Snippet

Sponsor: Materia Medica Holding | Conditions: Acute Respiratory Viral Infection | Phase 3 | Status: COMPLETED | Results posted: 2024-10-15